AntiArthritis Therapies 2005.
This meeting, hosted by Visiongain and B2B conferences, comprised approximately 35 delegates, predominantly from the pharmaceutical industry, and promoted interactive discussion. It covered a broad range of drug discovery and development activities, ranging from preclinical studies with compounds requiring further optimisation, through to launched drugs used in the treatment of arthritis today.
Braddock
Martin
M
Discovery Bioscience, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough LE11 5RH, Leicestershire, UK. Martin.Braddock@astrazeneca.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D000069285:Infliximab; D009288:Naproxen / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D020030:Nitric Oxide Donors / Q000494:pharmacology / Q000627:therapeutic use; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; C411103:HCT 3012; D020030:Nitric Oxide Donors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D009288:Naproxen; D000069285:Infliximab